Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy

In myelofibrosis (MF), driver mutations in JAK2, MPL, or CALR impact survival and progression to blast phase, with the greatest risk conferred by triple-negative status. Subclonal mutations, including mutations in high–molecular risk (HMR) genes, such as ASXL1, EZH2, IDH1/2, and SRSF2 have also been...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Spiegel, Jay Y., McNamara, Caroline, Kennedy, James A., Panzarella, Tony, Arruda, Andrea, Stockley, Tracy, Sukhai, Mahadeo, Thomas, Mariam, Bartoszko, Justyna, Ho, Jenny, Siddiq, Nancy, Maze, Dawn, Schimmer, Aaron, Schuh, Andre, Sibai, Hassan, Yee, Karen, Claudio, Jamie, Devlin, Rebecca, Minden, Mark D., Kamel-Reid, Suzanne, Gupta, Vikas
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2017
Soggetti:
Myeloid Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5728340/
https://ncbi.nlm.nih.gov/pubmed/29296819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017009530
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi